Global Tuberculosis Testing Market Report 2022: Rising the Prevalence of Drug-Resistant Tuberculosis Infection Driving Growth – ResearchAndMarkets.com

Global Tuberculosis Testing Market Report 2022: Rising the Prevalence of Drug-Resistant Tuberculosis Infection Driving Growth - ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Tuberculosis Testing Market (2022-2027) by Test Type, End-Users, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.

The Global Tuberculosis Testing Market is estimated to be USD 2.35 Bn in 2022 and is expected to reach USD 3.41 Bn by 2027, growing at a CAGR of 7.74%

Market Dynamics

Drivers

Rising the Prevalence of Drug-Resistant Tuberculosis Infection

Improvement in Bacteriological Confirmation

Increase in Awareness Enabling Proper Management of the Diseases

Restraints

Development of Advanced and Hybrid Technique of Multiple Disorder Detection

Opportunities

Rising Demand for Improved and Technologically Advanced Tuberculosis Testing Procedures

Growing Tuberculosis Awareness and Control Program

Challenges

Shortage of Supply of TST Antigens in Various Regions

Market Segmentations

The Global Tuberculosis Testing Market is segmented based on Test Type, End-Users, and Geography.

By Test Type, the market is classified into Culture Based Tests, Drug Susceptibility Testing, Nucleic Acid Testing, Radiography, and Smear Microscopy.

By End-Users, the market is classified into Hospital and Laboratories.

By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Tuberculosis Testing Market. Ansoff Matrix, also known as the Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

The analyst analyses the Global Tuberculosis Testing Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary

4 Market Dynamics

5 Market Analysis

6 Global Tuberculosis Testing Market, By Test Type

7 Global Tuberculosis Testing Market, By End-Users

8 Americas’ Tuberculosis Testing Market

9 Europe’s Tuberculosis Testing Market

10 Middle East and Africa’s Tuberculosis Testing Market

11 APAC’s Tuberculosis Testing Market

12 Competitive Landscape

13 Company Profiles

14 Appendix

Companies Mentioned

Abbott Laboratories

Advacare Pharma

Akonni Biosystems, Inc.

Apollo Diagnostics

Becton, Dickinson and Company

bioMerieux SA

Cepheid

Creative Diagnostics

Danaher Corp.

EpiLAB

F. Hoffmann-La Roche, Ltd.

Foresight Group, LLP

Hain Lifescience GmbH

Hologic, Inc.

Lionex Diagnostics & Therapeutics GmbH

Otsuka Pharmaceutical Co., Ltd.

Oxford Immunotec, Ltd.

Qiagen

Siemens Healthineers Ag

Thermo Fisher Scientific, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/5hhkuk

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.